Combinib 250 Mg Tablets

Combinib 250 mg tablet contains Lapatinib, a targeted cancer therapy belonging to the class of kinase inhibitors. It works by dual inhibition of HER2/ErbB2 and EGFR/ErbB1 receptors, blocking growth signals to cancer cells and inducing apoptosis (programmed cell death). Primarily used for HER2-positive breast cancer, it is typically taken on an empty stomach to treat advanced or metastatic disease.